Detorubicin (NSC 292652; RP 33921) is a semi-synthetic anthracycline anticancer agent and a hydrophobic prodrug of Doxorubicin ( HY-15142A ). Detorubicin enters cancer cells faster and achieves higher intracellular levels than Doxorubicin . Detorubicin localizes exclusively to lysosomes and the nucleus, with unmetabolized Detorubicin accumulating mainly in lysosomes. Detorubicin can be used in research related to hematologic malignancies and L1210 leukemia.
Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > Others | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Drug Intermediate
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.